2022
Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients
Ünlü S, Shin J, Par-Young J, Simonov M, Vinetz J, Petrylak D, Kang I, Kim J. Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients. Cancer Investigation 2022, 41: 77-83. PMID: 36373994, DOI: 10.1080/07357907.2022.2139839.Peer-Reviewed Original ResearchConceptsProstate cancer patientsCOVID-19 outcomesCancer patientsPoor COVID-19 outcomesAndrogen-androgen receptorExpression of TMPRSS2COVID-19 infectionSARS-CoV-2Directed therapyMean hospitalizationPCa patientsHospitalization ratesPCa casesRetrospective analysisOutcome differencesPatientsDefinitive conclusionsStatistical significanceData generate hypothesesHospitalizationTherapyTMPRSS2Cellular entryOutcomesARDTSemi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
Kosinsky Y, Peskov K, Stanski DR, Wetmore D, Vinetz J. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19. Microbiology Spectrum 2022, 10: e02167-21. PMID: 35412356, PMCID: PMC9047529, DOI: 10.1128/spectrum.02167-21.Peer-Reviewed Original ResearchConceptsFOY-251SARS-CoV-2 cell entryCamostat mesylateInhibition of TMPRSS2Viral loadClinical trialsCOVID-19Viral entrySerine protease inhibitorSpike proteinCell entryMultiple clinical trialsPharmacokinetic-pharmacodynamic modelSARS-CoV-2 viral entryPK/PDSARS-CoV-2Protease inhibitorsOne-compartmentCell surface serine proteaseViral entry inhibitionTMPRSS2 inhibitionViral surface spike proteinsAcute exacerbationSemi-mechanistic pharmacokinetic-pharmacodynamic modelsSARS-CoV-2 coronavirusEffect of androgen receptor directed therapy in prostate cancer patients with COVID-19.
Unlu S, Shin J, Par-Young J, Vinetz J, Petrylak D, Kang I, Kim J. Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19. Journal Of Clinical Oncology 2022, 40: 161-161. DOI: 10.1200/jco.2022.40.6_suppl.161.Peer-Reviewed Original ResearchProstate cancerPCa patientsAndrogen receptorCOVID-19Mortality rateYale New Haven Health SystemProtective rolePrevalence of PCaRate of hospitalRetrospective chart reviewExpression of TMPRSS2Rate of hospitalizationProstate cancer patientsAndrogen receptor antagonistProstate cancer casesSARS-CoV-2Institutional review boardDirected therapyChart reviewClinical characteristicsGnRH agonistHormone therapyGnRH antagonistHome medicationsClinical outcomes
2021
SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes
Pawlica P, Yario TA, White S, Wang J, Moss WN, Hui P, Vinetz JM, Steitz JA. SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2116668118. PMID: 34903581, PMCID: PMC8719879, DOI: 10.1073/pnas.2116668118.Peer-Reviewed Original ResearchConceptsBasic leucine zipper ATF-like transcription factor 2Small RNAsHuman lung-derived cell linesSARS-CoV-2 infectionLung-derived cell linesRNA interference (RNAi) pathwayHost miRNA levelsTranscription factor 2Cellular machineryInterference pathwayDrosha proteinSARS-CoV-2-infected individualsHost genesSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Host miRNAsPutative targetsSyndrome coronavirus 2SARS-CoV-2MiRNA levelsFactor 2Cell linesNasopharyngeal swabsCoronavirus 2